The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice

Immunosuppression is the mainstay of therapy for Glomerulonephritis (GN) with known rising costs due to newer, more expensive therapies; however the real world cost of this type of therapy has been largely unknown. This is a retrospective cohort study of GN patients on immunosuppression between 2000 and 2012 that uses linkage of pathology, renal and medication administrative databases to capture and evaluate characteristics of immunosuppression medications such as cost. Dr. Sean Barbour and colleagues have found that the yearly per patient cost of immunosuppression for GN have increased sharply in the treatment of certain types of GN that parallel the use of newer, expensive therapies for the treatment of GN such as Lupus Nephritis, ANCA associated vasculitis and Membranous nephropathy. The impact of these results, which may inform further studies and evidence based health policy, is also discussed.

Nephrology Dialysis Transplantation (PDF)